RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination
Journal for ImmunoTherapy of Cancer · 2023
DOI: 10.1136/jitc-2023-007313 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Yangyang Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Colonic Neoplasms, B7-H1 Antigen, DEAD Box Protein 58, Immune Evasion. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Zhongnan Hospital of Wuhan University, The Young Top-notch Talent Cultivation Program of Hubei Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Colon cancer is one of the most prevalent cancers and exhibits high mortality worldwide. Despite the certain success in the immunotherapy of many tumor types, the limited response of colon cancer to immunotherapy remains a difficult problem. Retinoic acid-inducible gene-I (RIG-I) is a crucial component in innate antiviral immunity, but its role in antitumor immunity remains unclear. Here, in this report, we found that silencing RIG-I decreased resistance to tumor cells killed by T cells and attenuated colon tumor growth in immunocompetent mice. Meanwhile, overexpressing RIG-I promoted tumor progression, and high expression of RIG-I sensitized cells to anti-programmed cell death protein-1 (PD-1) therapy in vivo. Interestingly, we found that RIG-I influenced programmed cell death ligand 1 (PD-L1) expression to promote colon cancer immune evasion without relying on type I interferon stimulation. Mechanistically, RIG-I could compete with Speckle Type POZ protein (SPOP) to bind PD-L1, leading to attenuation of the polyubiquitination and proteasomal degradation of PD-L1. Collectively, our work reveals new insights into the contribution of RIG-I to driving immune evasion by maintaining the stability of PD-L1 through post-translational modification and provides a promising biomarker of the efficacy of immunotherapy in colon cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
- Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China liujing_GI@whu.edu.cn studyong@outlook.com.
- Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China liujing_GI@whu.edu.cn studyong@outlook.com.
- Hubei Clinical Center & Key Lab of Intestinal & Colorectal Diseases, Wuhan University, Wuhan, Hubei, China.
ORCID-Profile: Jing Liu
Förderung
- Zhongnan Hospital of Wuhan University
- The Young Top-notch Talent Cultivation Program of Hubei Province
- National Natural Science Foundation of China
- Wuhan University
- Hubei Provincial Natural Science Foundation of China
Zitieren
APA
Zhang, Y., Zeng, L., Wang, M., Yang, Z., Zhang, H., Gao, L., Zhang, R., Liu, J., Shan, W., Chang, Y., Liu, L., Zhao, Q., Li, Y., & Liu, J. (2023). RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-007313
Vancouver
Zhang Y, Zeng L, Wang M, Yang Z, Zhang H, Gao L, et al. RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2023-007313
BibTeX
@article{Zhang2023,
author = {Zhang, Yangyang and Zeng, Lingxiu and Wang, Meng and Yang, Zhenwei and Zhang, Hailin and Gao, Liping and Zhang, Ranran and Liu, Jialong and Shan, Wenqing and Chang, Ying and Liu, Lan and Zhao, Qiu and Li, Yong and Liu, Jing},
title = {RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
doi = {10.1136/jitc-2023-007313}
}
EUVIMED